Prof. Joanna Wietrzyk

Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland

Prof. Joanna Wietrzyk

Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland

Co-authors

Following

Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 September 2016 in International Journal of Oncology

Journal Article

Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)

Ewa Maj

Diana Papiernik

Joanna Wietrzyk

The discovery of tumor angiogenesis opened a new path in fighting cancer. The approval of different antiangiogenic agents, most targeting vascular endothelial growth factor (VEGF) signaling, has either increased the effectiveness of standard chemotherapy or even replaced it by offering better patient outcomes. However, an increasing number of preclinical and clinical observations have shown that the process of angiogenesis is far from clearly understood. Apart from targeting the VEGF pathway, novel strategies aim to influence other molecular factors that are involved in tumor angiogenesis. In addition, naturally occurring compounds seem to offer additional agents for influencing angiogenesis. The first concept of antiangiogenic therapy aimed to destroy tumor vessels, while it turned out that, paradoxically, antiangiogenic drugs normalized vasculature and as a result offered an improvement in chemotherapeutic delivery. In order to design an effective treatment schedule, methods for detecting the time window of normalization and biomarkers predicting patient response are needed. The initial idea that antiangiogenic therapy would be resistance-free failed to materialize and currently we still face the obstacle of resistance to antiangiogenic therapy.

14 April 2020 in Molecules

Journal Article

Synthesis, Antiproliferative Activity and Molecular Docking Studies of Novel Doubly Modified Colchicine Amides and Sulfonamides as Anticancer Agents

Colchicine is a well-known compound with strong antiproliferative activity that has had limited use in chemotherapy because of its toxicity. In order to create more potent anticancer agents, a series of novel colchicine derivatives have been obtained by simultaneous modification at C7 (amides and sulfonamides) and at C10 (methylamino group) positions and characterized by spectroscopic methods. All the synthesized compounds have been tested in vitro to evaluate their cytotoxicity toward A549, MCF-7, LoVo, LoVo/DX and BALB/3T3 cell lines. Additionally, the activity of the studied compounds was investigated using computational methods involving molecular docking of the colchicine derivatives to β-tubulin. The majority of the obtained derivatives exhibited higher cytotoxicity than colchicine, doxorubicin or cisplatin against tested cancer cell lines. Furthermore, molecular modeling studies of the obtained compounds revealed their possible binding modes into the colchicine binding site of tubulin.

1 April 2014 in European Journal of Medicinal Chemistry

Journal Article

Synthesis, cytotoxicity and antibacterial activity of new esters of polyether antibiotic – salinomycin

Michał Antoszczak

Katarzyna Popiel

Joanna Stefańska

Joanna Wietrzyk

Ewa Maj

Adam Huczyński

1 December 2004 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Journal Article

Magnesium deficiency inhibits primary tumor growth but favors metastasis in mice

Anna Nasulewicz-Goldeman

Joanna Wietrzyk

Federica I. Wolf

Stanisław Dzimira

Janusz Madej

Adam Opolski

9 November 2018 in Molecules

Journal Article

Highly Cancer Selective Antiproliferative Activity of Natural Prenylated Flavonoids

Xanthohumol (XN) and four minor hops prenylflavonoids: α,β-dihydroxanthohumol (2HXN), isoxanthohumol (IXN), 8-prenylnaringenin (8PN), and 6-prenylnaringenin (6PN), were tested for antiproliferative activity towards human cancer and normal cell lines. Nonprenylated naringenin (NG) was used as a model compound. Xanthohumol, α,β-dihydroxanthohumol and 6-prenylnaringenin were the most active compounds. Xanthohumol exhibited higher antiproliferative activity than cisplatin (CP) against five cancer cell lines: ovarian resistant to cisplatin A2780cis, breast MDA-MB-231 and T-47D, prostate PC-3, and colon HT-29. Isoxanthohumol was more potent than cisplatin against breast cancer cell lines MDA-MB-231 and T-47D whereas 6-prenylnaringenin was stronger than cisplatin against breast cancer cell line T-47D. It was found that tested chalcones possessed highly selective antiproliferative activity towards all tested breast cancer lines compared to the normal breast MCF 10A cell line (the calculated selectivity index ranged from 5 to 10). Low antiproliferative activity of naringenin indicates the importance of the prenyl group with respect to antiproliferative activity.

17 April 2013 in Molecules

Journal Article

Synthesis, Structure and Cytotoxic Activity of New Acetylenic Derivatives of Betulin

A new series of betulin derivatives containing one or two pharmacophores bearing an acetylenic and carbonyl function at the C-3 and/or C-28 positions has been synthesized and characterized by ¹H- and ¹³C-NMR, IR, MS and elemental analyses. The crystal structure of 28-O-propynoylbetulin was determined by X-ray structural analysis. All new compounds, as well as betulin, were tested in vitro for their antiproliferative activity against human SW707 colorectal, CCRF/CEM leukemia, T47D breast cancer, and against murine P388 leukemia and Balb3T3 normal fibroblasts cell lines. Most of the compounds showed better cytotoxicity than betulin and cisplatin used as reference agent. 28-O-Propynoylbetulin was the most potent derivative, being over 500 times more potent than betulin and about 100 times more cytotoxic than cisplatin against the human leukemia (CCRF/CEM) cell line, with an ID₅₀ value of 0.02 μg/mL.

About Me

EDUCATION 1990–1996 Faculty of Veterinary Medicine, Agricultural Academy in Wroclaw, Poland 1996 the professional title of veterinarian (DVM) 2001 (28.06): doctor in biological sciences in the field of biology (PhD), specialization: cancers biology. 2010 (25.02): habilitated doctor in biological sciences in the field of biology, specialization: experimental oncology. 2018 (09.05): professor in biological sciences PROFESSIONAL CAREER COURSE After graduation, I started to work under the direction of professor Czesław Radzikowski, the head of the Department of Tumor Immunology at the Institute of Immunology and Experimental Therapy (IITD) PASc in Wroclaw. Since January 1997 I was employed at the Department as an assistant. In 2001, I was promoted to the position of an adjunct, in 2010 – assistant professor and in the same year – associate professor. Since February 2005- January 2017, I was the head of the Experimental Animal Facility IITD, and from 1 September 2006 to 30 April 2010 I played the duties of the head of the Laboratory of Experimental Anticancer Therapy, and from 1 May 2010, I have been the head of this Laboratory. In addition, since 01/10/2011, I started to work in the Jan Dlugosz Academy in Czestochowa at the Faculty of Mathematics and Natural Sciences as an associate professor (till September 2017).

Prof. Joanna Wietrzyk

Prof. Joanna Wietrzyk

Research Focus & Metrics

Academic Career Length

Publication Type Breakdown

Representative Publications

About Me